Migraines

Teva's Migraine Treatment Found Effective For Children As Young As 6

Cannabis Is Now The Best Solution For Migraine Headaches According To 3 New Medical Studies

Cannabis Eases Migraine Symptoms For 94% Of Users In Under 2 Hours: Study

Cannabis Is Now The Best Solution For Migraine Headaches According To 3 New Medical Studies

Cannabis Eases Migraine Symptoms For 94% Of Users In Under 2 Hours: Study

Vaporized Cannabis: A Promising Migraine Treatment, Suggests Study At American Headache Society Meeting

AbbVie's Migraine Treatment Drug Touts Encouraging Data In Preventive Treatment Setting

Vaporized Cannabis: A Promising Migraine Treatment, Suggests Study At American Headache Society Meeting

AbbVie's Migraine Treatment Drug Touts Encouraging Data In Preventive Treatment Setting

Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial

FDA Clears Tonix Pharma's Human Trial With Intranasal Oxytocin For Migraine

Migraines Recent News

Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M

FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie

Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study

Biohaven's Nurtec Wins FDA Approval As First Med to Prevent and Treat Migraine Attacks

FDA Accepts AbbVie's Atogepant US Review Application For Migraine

Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant

Satsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine

Satsuma Pharmaceuticals Inc (NASDAQ: STSA)

Teva's Preventive Migraine Treatment Approved By FDA

Cramer: Small-Cap Biotechs Are Reserved For Speculative Investors

Alder Biopharma Surged 60% Following Phase 2 Results